This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Journalology/ Peer Review/ Authorship  • Conflict of Interest  • Psychiatry, Other  • Statistics and Research Methods  • Humanities  • Medicine and the Media  • Alert me on articles by topic

Joseph T. Coyle, MD; Stephan Heckers, MD

Arch Gen Psychiatry. 2006;63(11):1178.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The issue of financial conflicts of interest in biomedical research and scientific publishing has been a thorny one with which JAMA, the ARCHIVES, and academic medicine have wrestled for nearly 2 decades.^1-3 Pharmaceutical, biotech, and, increasingly, medical device companies make major investments in sponsoring research in medical schools and pay for consultations with basic scientists and clinical investigators from academic medicine because of the expertise that they can bring to bear on therapeutic innovation. Many of the advances in the treatment of cancer, heart disease, and infectious disease are the fruits of these highly productive relationships. However, financial relationships between medical faculty and industry may not be obvious, unlike the identification of an individual as an employee of a particular company. Such financial relationships include participation in industry-sponsored clinical trials, membership on scientific advisory boards, stock or stock option ownership, . . . [Full Text of this Article]

AUTHOR INFORMATION